2007
DOI: 10.1097/qad.0b013e3280117053
|View full text |Cite
|
Sign up to set email alerts
|

Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy

Abstract: We studied a case of recent infection with multidrug-resistant (MDR) HIV-1. Over 16 months off-therapy, the CD4 cell count decreased from 419 to 184 cells/mul. Antiretroviral therapy (ART) then led to an incomplete virological response but to an immunological benefit, concurrently with a shift to CCR5-only tropism and a reduction in replication capacity. ART, even if suboptimal, can be of interest in the case of MDR virus infection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0

Year Published

2007
2007
2018
2018

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 13 publications
(8 citation statements)
references
References 12 publications
0
8
0
Order By: Relevance
“…There were a variety of factors which had effects on MMT retention rate [15]. The longer patients stayed in MMT clinic and no longer dependent on opioids, and receiving more supportive services, the more likely for patients to get better treatment outcome [9,16]. …”
Section: Discussionmentioning
confidence: 99%
“…There were a variety of factors which had effects on MMT retention rate [15]. The longer patients stayed in MMT clinic and no longer dependent on opioids, and receiving more supportive services, the more likely for patients to get better treatment outcome [9,16]. …”
Section: Discussionmentioning
confidence: 99%
“…In 2004, the Chinese government pilot tested eight MMT clinics to address the dual epidemics of HIV and drug use (Pang et al, 2007). Based on results showing a reduction in heroin use, intravenous injection, and drug-related crime, the national MMT program was scaled up rapidly.…”
Section: Introductionmentioning
confidence: 99%
“…R5 variants predominate during acute and early infection and generally persist throughout the entire course of HIV-1 infection (Berger, Murphy, and Farber, 1999). In contrast, CXCR4-using variants (dual and, to a lesser extent, X4 viruses) are detected infrequently in recent infections (Eshleman et al, 2007; Huang et al, 2009; Markowitz et al, 2005; Masquelier et al, 2007), but gradually increase in prevalence as chronic infection ensues (Berger, Murphy, and Farber, 1999; Connor et al, 1997; Melby et al, 2006; Schuitemaker et al, 1992; Wilkin et al, 2007). Generally, CXCR4-using variants are found in approximately 20% of antiretroviral (ARV) treatment-naïve individuals, characterized by higher CD4+ T-cell counts (Brumme et al, 2005; Moyle et al, 2005), and approximately 50% of highly treatment-experienced patients, characterized by low CD4+ T-cell counts (Coakley et al, 2006; Demarest et al, 2004; Hunt et al, 2006; Melby et al, 2006; Wilkin et al, 2007).…”
Section: Introductionmentioning
confidence: 99%